IMC-U120AI / Immunocore - LARVOL DELTA

IMC-U120AI (CD1a) for atopic dermatitis as the initial indication - first universal program (GlobeNewswire) - "The Company plans to file a CTA/IND for IMC-U120AI (CD1a x PD1) in 2026."

IND • Atopic Dermatitis

Immunocore reports second quarter financial results and provides a business update (GlobeNewswire) - "IMC-U120AI (CD1a) for atopic dermatitis as the initial indication - first universal program: The Company plans to file a CTA/IND for IMC-U120AI (CD1a x PD1) in 2026."

IND • Atopic Dermatitis

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update (GlobeNewswire) - "The Company continues to enroll people living with HIV (PLWH) in the multiple ascending dose (MAD) part of the Phase 1 clinical trial with IMC-M113V and will present data from the initial three cohorts during the first quarter of 2025...The Company completed the single ascending dose (SAD) portion of the Phase 1 trial with IMC-I109V for people living with hepatitis B virus (HBV) and plans to present this data in the second half of 2025...The Company plans to file a CTA or investigational new drug application (IND) for IMC-S118AI (PPI x PD1) in the second half of 2025...The Company plans to file a CTA/IND for IMC-U120AI in 2026, initially for a Phase 1 dose escalation trial in atopic dermatitis."

IND • P1 data • Atopic Dermatitis • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Type 1 Diabetes Mellitus